Standout Papers

GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes 2024 202653
  1. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes (2024)
    Duy Ngoc, Samuel K. Peasah et al. JAMA Network Open

Immediate Impact

43 standout
Sub-graph 1 of 18

Citing Papers

GLP-1-based therapies for diabetes, obesity and beyond
2025 Standout
Psychotropic Drug–Related Weight Gain and Its Treatment
2024 Standout
3 intermediate papers

Works of Urvashi Patel being referenced

GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes
2024 Standout
The Impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on Prescribing Practices
2011

Author Peers

Author Last Decade Papers Cites
Urvashi Patel 109 38 40 143 56 25 357
Jane B. Neese 218 22 51 82 65 19 372
Donna Jo McCloskey 136 20 27 84 50 18 402
Gayathri Embuldeniya 193 30 18 60 39 16 346
Nataly R. Espinoza Suárez 191 48 14 86 68 32 342
B Claussen 124 6 14 65 28 15 391
Ruba M. Jaber 123 27 16 74 49 22 369
Miriam Mutambudzi 167 10 23 48 53 32 377
Ezra Gabbay 73 22 10 73 48 27 363
Moosa Sajjadi 76 9 13 133 87 41 345
Arfan R. Afzal 76 9 11 64 38 31 382

All Works

Loading papers...

Rankless by CCL
2026